[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352226-105":59,"doc-detail-352226-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-esophageal-cancer-promising-drugs-for-the-clinical-landscape-and-key-knowledge-gaps","Targeting Esophageal Cancer - Promising Drugs for the Clinical Landscape and Key Knowledge Gaps","","Esophageal cancer remains a major global health burden, with a poor prognosis for metastatic disease and durable responses limited by tumor heterogeneity and treatment resistance. Biomarker-driven therapy is reshaping management by enabling more personalized treatment selection. This narrative review synthesizes clinical strategies and emphasizes clinically validated biomarkers, including HER2, PD-L1, CLDN18.2, and MMR/MSI status, with focus on advanced metastatic settings and EAC. The review summarizes key phase II–III trial evidence and evaluates early-phase advances such as antibody-drug conjugates, novel monoclonal antibodies, and cellular therapies. It also addresses major challenges and outlines research directions for improved biomarkers and resistance mitigation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-esophageal-cancer-promising-drugs-for-the-clinical-landscape-and-key-knowledge-gaps/352226/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-esophageal-cancer-promising-drugs-for-the-clinical-landscape-and-key-knowledge-gaps/352226.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is esophageal cancer difficult to treat effectively?","Question",{"text":112,"@type":113},"Tumor heterogeneity and the emergence of treatment resistance limit durable responses to conventional chemotherapy. Molecular differences across subtypes also contribute to variability in outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers are highlighted for guiding therapy in advanced metastatic esophageal cancer?",{"text":117,"@type":113},"The review emphasizes clinically validated biomarkers including HER2, PD-L1, CLDN18.2, and MMR/MSI status. These biomarkers help inform therapeutic selection.",{"name":119,"@type":110,"acceptedAnswer":120},"What new treatment modalities does the review discuss beyond established therapies?",{"text":121,"@type":113},"The review summarizes early-phase data for promising approaches such as antibody-drug conjugates, novel monoclonal antibodies, and cellular therapies. It highlights biomarker associations and mechanisms of action.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352226,1790145840,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Drug Design, Development and Therapy  \nOpen Access Full Text Article REVIEW  \nTargeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps  \nTerzungwe Akumaga 1 , Haeseong Park2 , A Craig Lockhart 3 , Ramon U Jin 1 ,4  \n1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 3Division of Hematology/Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA; 4Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA  \nCorrespondence: Ramon U Jin, Divisions of Oncology and Gastroenterology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA, Email [jinr@wustl.edu](jinr@wustl.edu)  \n\n| Abstract: Esophageal cancer remains a major global health burden, ranking seventh in cancer-related mortality. The prognosis is poor with five-year survival rates below 5% for metastatic disease. Tumor heterogeneity and the development of treatment resistance have limited durable responses to conventional chemotherapy. The emergence of biomarker-driven therapies has begun to transform management and enable more personalized treatment approaches. This narrative review summarizes current clinical strategies for esophageal cancer, emphasizing clinically validated biomarkers —HER2, PD-L1, CLDN18.2, and MMR/MSI status—that inform therapeutic selection for advanced metastatic disease. Both esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are addressed; however, this review centers on biomarker-directed therapies for EAC, reflecting its predominance in Western populations and recent therapeutic progress. We highlight pivotal phase II and III clinical trials that have established the current landscape of esophageal cancer treatment. In addition, we review key early phase clinical data for promising new modalities such as antibody-drug conjugates, novel monoclonal antibodies, and cellular therapies—highlighting their biomarker associations and mechanisms of action. Finally, we discuss the ongoing challenges—including elucidating tumor heterogeneity, improving biomarkers, targeting novel tumor intrinsic vulnerabilities, overcoming treatment resistance, and preventing esophageal cancer development—and identify key research directions that present unique opportunities for the development of new biomarker-driven treatments for esophageal cancer.\u003Cbr>Keywords: Gastroesophageal, targeted therapy, immunotherapy, tumor microenvironment |\n| --- |\n| Introduction\u003Cbr>Esophageal cancer is a common, aggressive malignancy with high global incidence and mortality. According to GLOBOCAN estimates, over 510,000 new cases and more than 450,000 deaths occurred in 2022, making it the seventh leading cause of cancer deaths worldwide.1 In the US, over 22,000 new cases and 16,000 deaths are projected for 2025.2 Survival remains dismal with only 5% of patients with metastatic disease surviving five years.2 Clinical presentation often includes symptoms of esophageal luminal narrowing such as dysphagia, weight loss, odynophagia, and regurgitation.3 Physical findings of advanced disease may include lymphadenopathy, hoarseness from laryngeal nerve involvement, pleural effusions, ascites, hepatomegaly, bony tenderness, or upper gastrointestinal (GI) bleeding.4 Esophageal cancer includes two main histologic subtypes: esophageal adenocarcinoma (EAC), more common in Western countries and linked to Barrett’s esophagus (BE);5 and esophageal squamous cell carcinoma (ESCC), more common in Asia and associated with tobacco and alcohol use.6 Anatomically, esophageal cancers are classified as upper, middle, or lower.7 Distal tumors near the gastroesophageal junction (GEJ) are further categorized by Siewert classification.8 Type I and II Siewert tumors, located within","cbCairEjluCwFPsa","https://ap.wps.com/l/cbCairEjluCwFPsa","pdf",2077248,28,"English","# Introduction\n## Clinical burden and prognosis\n## Histologic subtypes and classification\n## Tumor heterogeneity and molecular diversity\n# Biomarker-Driven Clinical Strategies\n## HER2, PD-L1, CLDN18.2, and MMR/MSI\n## Therapeutic selection in advanced metastatic disease\n# Emerging Modalities and Early-Phase Evidence\n## Antibody-drug conjugates\n## Novel monoclonal antibodies\n## Cellular therapies and biomarker associations\n# Key Knowledge Gaps and Future Directions","[{\"question\":\"Why is esophageal cancer difficult to treat effectively?\",\"answer\":\"Tumor heterogeneity and the emergence of treatment resistance limit durable responses to conventional chemotherapy. Molecular differences across subtypes also contribute to variability in outcomes.\"},{\"question\":\"Which biomarkers are highlighted for guiding therapy in advanced metastatic esophageal cancer?\",\"answer\":\"The review emphasizes clinically validated biomarkers including HER2, PD-L1, CLDN18.2, and MMR/MSI status. These biomarkers help inform therapeutic selection.\"},{\"question\":\"What new treatment modalities does the review discuss beyond established therapies?\",\"answer\":\"The review summarizes early-phase data for promising approaches such as antibody-drug conjugates, novel monoclonal antibodies, and cellular therapies. It highlights biomarker associations and mechanisms of action.\"}]","Targeting Esophageal Cancer - Promising Drugs for the Clinical Landscape and Key Knowledge Gaps | PDF",1790098422,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/454587a8d760fdcc10b4b13a7debfa7e.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa83e318fd6328b70ed60b6c9d9ee8e4.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfd13c487a68f6b9dc2cce22721fa220.webp",981,757,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/926f719d408089b4926eb952796f819c.webp",980,756]